Semaglutide versus tirzepatide

Why readers compare the two drugs

Readers who compare these two drugs usually want to know how they differ and which one is being proposed to them. The routine concerns are about how each drug works. The harder ones are about status and about what a patient is being asked to accept.

NHS describes tirzepatide as a dual agonist that activates the gut hormone receptors GLP-1 and GIP to increase the levels of these hormones in your body. For semaglutide injection, MedlinePlus (NIH) says it also slows the emptying of the stomach and may decrease appetite and cause weight loss. MedlinePlus (NIH) says tirzepatide injection also slows the emptying of the stomach and may decrease appetite and cause weight loss.

Three questions, in order

Read them in this order, from how the drugs work to how to choose.

• Dual incretin therapy, what makes tirzepatide different? A question about how the drug works.
• Is semaglutide approved for weight loss? A question about status.
• Comparing semaglutide and tirzepatide, what should patients weigh? The question that turns the other two into a decision.

Background on the condition itself

The reference pages below cover the condition and one of the drugs. MedlinePlus keeps an overview of obesity, and Cleveland Clinic explains what obesity is, its classes, symptoms and causes. For the drug itself, there is a MedlinePlus drug information page on tirzepatide injection.

What to ask before you commit to either drug

Ask the clinic which of the two it is proposing and why, in words you could repeat to your own doctor. If the answer depends on a brand name and not on your situation, ask again.